Literature DB >> 11871462

Pathogenesis of HIV-associated cardiovascular complications.

G Barbaro1, S D Fisher, S E Lipshultz.   

Abstract

Reviews and studies published before the introduction of highly active antiretroviral therapy (HAART) have tracked the incidence and course of HIV infection in relation to cardiac illness in both children and adults. The introduction of HAART regimens has significantly modified the course of HIV disease, with longer survival rates and improvement of life quality in HIV-infected people expected. However, early data raised concerns about HAART being associated with an increase in both peripheral and coronary arterial diseases. In this review we discuss HIV-associated cardiovascular complications focusing on pathogenetic mechanisms that could have a role in diagnosis, management, and therapy of these complications in the HAART era.

Entities:  

Mesh:

Year:  2001        PMID: 11871462     DOI: 10.1016/S1473-3099(01)00067-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  28 in total

1.  A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.

Authors:  Karim Sacre; Peter W Hunt; Priscilla Y Hsue; Ekaterina Maidji; Jeffrey N Martin; Steven G Deeks; Brigitte Autran; Joseph M McCune
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia.

Authors:  Pranjali N Dalvi; Vijayalaxmi G Gupta; Brooke R Griffin; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

3.  Myocardial and Pericardial Disease in HIV.

Authors:  William G. Harmon; Gul H. Dadlani; Stacy D. Fisher; Steven E. Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-12

Review 4.  Neural effects of inflammation, cardiovascular disease, and HIV: Parallel, perpendicular, or progressive?

Authors:  C L Nemeth; M Bekhbat; G N Neigh
Journal:  Neuroscience       Date:  2014-09-17       Impact factor: 3.590

5.  Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways.

Authors:  Cheryl Twu; Nancy Q Liu; Waldemar Popik; Michael Bukrinsky; James Sayre; Jaclyn Roberts; Shammas Rania; Vishnu Bramhandam; Kenneth P Roos; W Robb MacLellan; Milan Fiala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-11       Impact factor: 11.205

6.  HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cells.

Authors:  Jun Jiang; Weiping Fu; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Cardiovasc Res       Date:  2010-01-18       Impact factor: 10.787

7.  Massive occlusive thrombosis of the pulmonary artery in pigtailed macaques chronically infected with R5-tropic simian-human immunodeficiency virus.

Authors:  Cynthia L Courtney; Kelly F Ethun; Francois Villinger; Ruth M Ruprecht; Siddappa N Byrareddy
Journal:  J Med Primatol       Date:  2014-09-01       Impact factor: 0.667

8.  Peripheral edema with hypoalbuminemia in a nonhuman primate infected with simian-human immunodeficiency virus: a case report.

Authors:  Carol L Clarke; Michael A Eckhaus; Patricia M Zerfas; William R Elkins
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-01       Impact factor: 1.232

Review 9.  Cardiac manifestations of HIV infection: an African perspective.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

10.  Cardiac anomalies in a group of HIV-infected children in a pediatric hospital: an echocardiographic study in Yaounde, Cameroon.

Authors:  David Chelo; Edvine Wawo; Valentin Siaha; Aurelien Anakeu; Francis Ateba Ndongo; Paul Olivier Koki Ndombo; Samuel Kingue
Journal:  Cardiovasc Diagn Ther       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.